Lake Street Capital Cuts Achieve Life Sciences Price Target to 11.00
ACHV Stock | USD 4.49 0.01 0.22% |
Slightly above 55% of Achieve Life's investor base is interested to short. The analysis of the overall investor sentiment regarding Achieve Life Sciences suggests that many traders are impartial. Achieve Life's investing sentiment can be driven by a variety of factors including economic data, Achieve Life's earnings reports, geopolitical events, and overall market trends.
Achieve |
Achieve Life Sciences had its price objective lowered by Lake Street Capital from 19.00 to 11.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Separately, Oppenheimer dropped their target price on shares of Achieve Life Sciences from 21.00 to
Read at thelincolnianonline.com
Achieve Life Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Achieve Life can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Achieve Life Fundamental Analysis
We analyze Achieve Life's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Achieve Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Achieve Life based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Achieve Life is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Achieve Life Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Achieve Life stock to make a market-neutral strategy. Peer analysis of Achieve Life could also be used in its relative valuation, which is a method of valuing Achieve Life by comparing valuation metrics with similar companies.
Peers
Achieve Life Related Equities
IMMX | Immix Biopharma | 19.39 | ||||
XFOR | X4 Pharmaceuticals | 11.26 | ||||
ASMB | Assembly Biosciences | 10.72 | ||||
CTMX | CytomX Therapeutics | 6.25 | ||||
BOLT | Bolt Biotherapeutics | 5.00 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
ITOS | Iteos Therapeutics | 4.27 | ||||
TCRX | Tscan Therapeutics | 2.80 | ||||
ABOS | Acumen Pharmaceuticals | 2.73 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
DAWN | Day One | 1.33 | ||||
CHRS | Coherus BioSciences | 1.56 | ||||
SPRO | Spero Therapeutics | 1.74 | ||||
NXTC | NextCure | 2.50 | ||||
HEPA | Hepion Pharmaceuticals | 4.33 | ||||
CNSP | Cns Pharmaceuticals | 7.69 |
Additional Tools for Achieve Stock Analysis
When running Achieve Life's price analysis, check to measure Achieve Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achieve Life is operating at the current time. Most of Achieve Life's value examination focuses on studying past and present price action to predict the probability of Achieve Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achieve Life's price. Additionally, you may evaluate how the addition of Achieve Life to your portfolios can decrease your overall portfolio volatility.